Takeaways: Optimi Health’s plan to start a Health Canada‑authorized Phase 3 trial of synthetic MDMA‑assisted therapy for PTSD in 2027 positions the company to potentially become an early mover i...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
